bZIP60 is an ER membrane-bound transcription factor activated through proteolytic processing or mRNA splicing during ER stress. It contains:
N-terminal bZIP domain (DNA-binding region)
Transmembrane domain (anchors to ER membrane)
Under stress (e.g., tunicamycin, DTT), bZIP60 is processed to release its N-terminal fragment, which translocates to the nucleus to upregulate ER chaperones like BiP and PDI .
The BZIP60 antibody has been pivotal in characterizing protein dynamics and localization:
Proteolytic vs. Splicing Activation:
Initial studies suggested proteolytic cleavage , but subsequent work showed IRE1-mediated mRNA splicing removes a 23-bp intron, producing a truncated protein (bZIP60s) . Antibodies distinguished between the full-length (bZIP60u, 295 aa) and spliced (bZIP60s, 258 aa) forms .
Subcellular Localization:
Immunofluorescence confirmed ER retention of unprocessed bZIP60 and nuclear translocation of the spliced form under stress .
The antibody helped elucidate bZIP60’s immune functions:
Pathogen Defense:
Signaling Crosstalk:
bZIP60 cooperates with salicylic acid (SA) pathways to enhance systemic acquired resistance (SAR), as shown by reduced PR1 expression in ire1a/ire1b and bzip60 mutants .
Specificity: Polyclonal antibodies against the N-terminal bZIP domain reliably detect both isoforms without cross-reactivity to related proteins like bZIP28 .
Quantitative Use: CE-LIF and qRT-PCR correlated antibody-detected protein levels with spliced mRNA abundance during viral (TuMV) infection .
Low Spliced Isoform Detection: Spliced bZIP60 mRNA forms stable secondary structures, reducing reverse transcription efficiency. Optimized primers and antibody combinations resolved this .
Functional Redundancy: bZIP60 partially overlaps with bZIP28; dual mutants (bzip28/bzip60) are required for phenotypic analysis .